If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Medical Affairs » Medical Science Liaison
Download FREE Excerpt
3 Info Graphics
12 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
As the role of Medical Science Liaisons (MSLs) continues to evolve around the globe, pharmaceutical companies are continuously re-evaluating and updating their guidelines for scientific interactions between MSLs and Healthcare Practitioners (HCPs) in countries and regions outside the United States.
This study presents insights on current MSL practices around HCP interactions outside the US; topics addressed include proactive disease presentations, unsolicited requests on clinical data and off-label uses, and group HCP presentations. There are also questions about MSL re-certification.
Leaders of global or Non-US pharmaceutical field medical teams can use this research to see how their approach to MSL interactions with Non-US HCPs compares with current industry practices for scientific interactions between MSLs and Non-US-based HCPs, including gray areas such as off-label questions and group HCP presentations.
This study engaged 9 non-US medical affairs leaders from 9 world-class biopharmaceutical companies. Fifty – six percent of the respondents are at the Director level (5); 22% at Head (2), 11% at Lead (1) and 11% at Manager (1).